Treatment of peptic ulcer of the stomach and duodenum.
Composition:
1 tabl contains 1 g of sucralfate.
Action:
The preparation accelerates the healing of gastric and duodenal ulcers. The drug has no systemic effect - it works locally, forming a protective layer using necrotic tissue proteins at the ulcer site. This layer prevents the digestive effect of pepsin, gastric acid and bile salts. Inhibition of pepsin activity reaches about 30%. Sucralfate prevents the absorption of phosphates from the gastrointestinal tract. Only 5% of the administered sucralfate is absorbed from the gastrointestinal tract. 0.005% of the aluminum contained in the drug is absorbed. Absorbed sucralfate and aluminum do not undergo metabolism; they are expelled from the body unchanged in the urine. Most of the administered drug is eliminated unchanged in the faeces, without absorption from the gastrointestinal tract.
Contraindications:
Hypersensitivity to sucralfate or to any of the excipients.
Precautions:
In patients with severe kidney problems, aluminum may accumulate in the body; the risk of such accumulation increases with the simultaneous administration of other aluminum-containing medications (some antacids). Aluminum accumulated in the body may have toxic effects. Formation of bezoars after administration of sucralfate was reported mainly in seriously ill patients in intensive care units. The majority of patients (including newborns for whom sucralfate is not recommended) have conditions that may predispose to the formation of bezoaras (eg delayed gastric emptying due to the use of other medications, surgical procedures or diseases that reduce mobility), or have been nourished using an enteric tube. It is not recommended for use in children and adolescents under 14 years of age due to a lack of data on safety and efficacy.
Pregnancy and lactation:
Sucralfate can be used during pregnancy if the beneficial effect on mother's health justifies the potential risk to the child - caution should be exercised when using the product during pregnancy. It is not known whether sucralfate is excreted in breast milk - caution is advised when using the drug during breastfeeding.
Side effects:
Common: constipation. Uncommon: pain and dizziness, drowsiness, diarrhea, vomiting, nausea, bloating, dry mouth. Rare: abdominal discomfort, lower back pain. Very rare: rash, urticaria, pruritus. In patients with renal impairment, there may be an increase in the aluminum concentration in the tissues. There is a possibility of aluminum toxicity (encephalopathy).
Dosage:
Orally. Adults and adolescents over 14 years old: 1 g of sucralfate 4 times a day (1 table before each main meal (breakfast, lunch, dinner) and 1 table immediately before going to sleep). The preparation can also be taken at a dose of 2 g (2 tablets) 2 times a day. Healing of the ulcer usually takes place in the period of 4-6 weeks of treatment. The preparation should be used for at least 4 to 8 weeks or until the ulcer has been confirmed in the tests. If necessary, you can prolong the administration of the drug, however, the treatment should not last longer than 12 weeks. No dosage adjustment is necessary for patients with renal insufficiency. The preparation should be taken on an empty stomach, 1 / 2-1 h before a meal. The tablets can be washed with liquid or dissolved in half a glass of water and drunk.
(C)
